The FDA unveiled a new report on initiatives to drive biomedical innovation, including outreach to small businesses, support for personalized medicine, creation of a rapid development path for important targeted drugs and more.

The FDA continued to add more drugs and biologics to its shortage list, including cancer drug paclitaxel.